胡亞暖,姚永明,張澤敏,張 帆,王 君,楊彪炳
(1.濰坊醫(yī)學(xué)院整形外科 山東 濰坊 261053;2.費(fèi)縣人民醫(yī)院 山東 臨沂 273400;3. 濰坊醫(yī)學(xué)院整形外科研究所 山東 濰坊 261053)
不同濃度EGF對(duì)兔ADSCs體外誘導(dǎo)分化為表皮細(xì)胞的實(shí)驗(yàn)研究
胡亞暖1,姚永明1,張澤敏1,張帆2,王君1,楊彪炳3
(1.濰坊醫(yī)學(xué)院整形外科山東 濰坊261053;2.費(fèi)縣人民醫(yī)院山東 臨沂273400;3. 濰坊醫(yī)學(xué)院整形外科研究所山東 濰坊 261053)
目的:探究表皮生長(zhǎng)因子(EGF)對(duì)兔脂肪來(lái)源干細(xì)胞(ADSCs)體外誘導(dǎo)分化為表皮細(xì)胞以及所需最佳濃度的實(shí)驗(yàn)研究,為組織工程在大面積皮膚缺損方面的研究提供進(jìn)一步的理論依據(jù)。方法:取2個(gè)月齡健康新西蘭大白兔的脂肪組織,體外分離、培養(yǎng)并傳代ADSCs。實(shí)驗(yàn)分為誘導(dǎo)組和未誘導(dǎo)組,誘導(dǎo)組分別用5ng/ml、10ng/ml、20ng/ml的EGF進(jìn)行干預(yù),未誘導(dǎo)組用等量的生理鹽水作空白對(duì)照。觀察不同濃度的EGF對(duì)ADSCs誘導(dǎo)分化為表皮細(xì)胞的形態(tài)學(xué)變化,并于1周后對(duì)細(xì)胞進(jìn)行免疫熒光及熒光定量PCR檢測(cè)CK-19和整合素β(integrinβ)的表達(dá)情況。結(jié)果:光鏡下顯示誘導(dǎo)組細(xì)胞形態(tài)仍呈長(zhǎng)梭形或多角形;免疫熒光結(jié)果顯示誘導(dǎo)組(10ng/ml組)表皮細(xì)胞特異性標(biāo)記物CK-19表達(dá)呈陽(yáng)性,且其表達(dá)量明顯高于其他組,未誘導(dǎo)組細(xì)胞呈陰性;熒光定量PCR結(jié)果顯示誘導(dǎo)組(10ng/ml組)表皮細(xì)胞的特異性因子CK-19和integrinβ的mRNA表達(dá)量均明顯高于其余組(P<0.01)。結(jié)論:表皮生長(zhǎng)因子能夠成功誘導(dǎo)兔脂肪來(lái)源干細(xì)胞定向分化為表皮細(xì)胞,且其最佳誘導(dǎo)濃度為10ng/ml。
脂肪來(lái)源干細(xì)胞;表皮生長(zhǎng)因子;表皮細(xì)胞;濃度
Key worlds: adipose derived stem cells; EGF; epidermis cells; concentration
大面積皮膚缺損是外科領(lǐng)域中的一項(xiàng)重大難題。目前,自體皮膚移植是治療皮膚組織缺損的一種有效方法。然而,自體皮膚移植供區(qū)的皮膚來(lái)源有限,對(duì)患者的創(chuàng)傷較大,同時(shí)刃厚皮片存在不耐摩擦、缺乏彈性及易收縮等特點(diǎn),中厚皮片又有瘢痕攣縮等問題。隨著組織工程技術(shù)的發(fā)展,皮膚替代物的研究取得了實(shí)質(zhì)性的進(jìn)展。脂肪來(lái)源干細(xì)胞(adipose-derived stem cells,ADSCs)是從脂肪組織中分離出來(lái)的多能干細(xì)胞,經(jīng)誘導(dǎo)后,可以向骨、軟骨、脂肪、肌肉、血管內(nèi)皮以及表皮細(xì)胞分化[1-2],成為了繼骨髓間充質(zhì)干細(xì)胞[3]之后的又一研究熱點(diǎn)。本實(shí)驗(yàn)旨在探討不同濃度的表皮生長(zhǎng)因子( epidermal growth factor,EGF)對(duì)兔ADSCs誘導(dǎo)分化為表皮細(xì)胞的機(jī)制,以及尋找其最佳誘導(dǎo)濃度,以提高細(xì)胞培養(yǎng)成效,為今后臨床大面積皮膚組織缺損的治療提供了一定的理論依據(jù)。
1.1實(shí)驗(yàn)動(dòng)物及主要試劑、儀器:新西蘭大白兔(2~3個(gè)月齡)(購(gòu)自濰坊醫(yī)學(xué)院動(dòng)物中心);DMEM培養(yǎng)基(高糖)(美國(guó)HyClone有限公司);胎牛血清(杭州四季青生物工程材料有限公司);EGF(北京博奧森生物技術(shù)有限公司);CK-19單克隆抗體(北京博奧森生物技術(shù)有限公司);反轉(zhuǎn)錄試劑盒(上海生工生物工程技術(shù)服務(wù)有限公司);SYBR Green熒光定量試劑盒(TAKARA)。
SW-CJ-1F型超凈工作臺(tái)(中國(guó));Heraews 二氧化碳培養(yǎng)箱(德國(guó));DMIL型倒置相差顯微鏡(德國(guó)Leica);熒光PCR儀(澳大利亞Corbett);KA-1000型低速離心機(jī)(鄭州南北儀器設(shè)備公司);多功能冷凍離心機(jī)(德國(guó)Heraeus)。
1.2ADSCs的分離、培養(yǎng)、傳代以及鑒定:取大白兔新鮮脂肪,放置于無(wú)菌盤中,用PBS緩沖液沖洗3遍,剔除肉眼可見的小血管、包膜以及多余的組織,再次用無(wú)菌PBS沖洗3遍,剪成糊狀,于室溫環(huán)境中1 200r/min離心5min,用0.1%Ⅰ型膠原酶消化50min,經(jīng)200目篩網(wǎng)過濾后,加入DMEM培養(yǎng)液終止消化,室溫下1 200r/min離心10min,棄上清,留貼壁細(xì)胞;用低糖DMEM培養(yǎng)液重懸并接種至培養(yǎng)瓶中,在37℃、5%CO2的培養(yǎng)箱中孵育,24h后觀察細(xì)胞貼壁情況,48h進(jìn)行首次換液,以后每2d換液一次。待細(xì)胞融合到培養(yǎng)瓶底80%~90%時(shí),進(jìn)行細(xì)胞傳代,每2d換液一次。取第3代細(xì)胞用細(xì)胞免疫熒光染色法檢測(cè)ADSCs表面特異性標(biāo)記物CD34、CD44、CD29及CD106。
1.3EGF誘導(dǎo)ADSCs后CK-19的表達(dá):用第3代ADSCs作為實(shí)驗(yàn)細(xì)胞。將細(xì)胞接種于96孔板中,接種密度為1×103/孔,培養(yǎng)至生長(zhǎng)階段,分為兩組:EGF誘導(dǎo)組和未誘導(dǎo)組。EGF實(shí)驗(yàn)組在 96 孔板加入含有不同質(zhì)量濃度EGF ( 5、10、20ng/ml)的DMEM培養(yǎng)液,各濃度設(shè)復(fù)孔;未誘導(dǎo)組不加EGF,亦設(shè)復(fù)孔。每隔48h換液1次,在 37℃、5% CO2條件下培養(yǎng)。1周后按照免疫熒光染色試劑盒說(shuō)明對(duì)表皮細(xì)胞的特異性標(biāo)志物CK-19進(jìn)行檢測(cè)。
1.4熒光定量PCR檢測(cè)誘導(dǎo)后CK-19和integrinβ的mRNA表達(dá):將定向誘導(dǎo)分化1周后的表皮細(xì)胞在培養(yǎng)瓶中用TRIZOL提取總的mRNA。以總的mRNA為模板,按照試劑盒說(shuō)明書進(jìn)行逆轉(zhuǎn)錄和PCR反應(yīng)。逆轉(zhuǎn)錄采用20μl的反應(yīng)體系:總RNA 4μl、5×gDNA Eraser buffer 2μl、RNase free dH2O 3μl、gDNA Eraser1μl,混勻后42℃ 2min;繼續(xù)加入5×PrimeScript Buffer2 4μl、RNase free dH2O 4μl,混勻離心加入RT Prime Mix 1μl,PrimeScript RT Enzyme MixI 1μl。反應(yīng)條件:37℃15min、85℃5s。PCR采用12.5μl的反應(yīng)體系:SYBR Green Mix 6.25μl、cDNA模板1μl、PCR Forward Primer 0.5μl、PCR Reverse Primer 0.5μl、RNase free dH2O 4.25μl。反應(yīng)條件:94℃ 3min、94℃ 30s、60.8℃ 30s、72℃ 30s,40個(gè)循環(huán),72℃延伸10min。檢測(cè)CK-19和integrinβ mRNA的表達(dá)。采用2-ΔΔCt方法計(jì)算各組基因相對(duì)表達(dá)量。
1.5統(tǒng)計(jì)學(xué)方法:采用目的基因Ct值/內(nèi)參Ct值進(jìn)行CK-19和integrinβ mRNA的相對(duì)定量分析。相對(duì)定量值越低說(shuō)明其表達(dá)量越高。采用SPSS19.0統(tǒng)計(jì)軟件進(jìn)行分析。數(shù)據(jù)以均數(shù)±標(biāo)準(zhǔn)差表示,各組間比較采用方差分析,兩兩比較采用 SNK檢驗(yàn);檢驗(yàn)水準(zhǔn)α=0.05。
2.1ADSCs形態(tài)學(xué)觀察及免疫熒光細(xì)胞化學(xué)染色鑒定:原代細(xì)胞最初呈圓形透亮,與脂滴共同漂浮于培養(yǎng)液中。6~8h開始沉降貼壁,貼壁后細(xì)胞多為短梭形、星形或小多角形。24h后貼壁細(xì)胞充分伸展,培養(yǎng)至第7天,細(xì)胞鋪滿瓶底,排列較整齊,并形成集落,彼此融合呈長(zhǎng)梭形分布(圖1)。免疫熒光細(xì)胞化學(xué)染色檢測(cè)結(jié)果顯示,ADSCs特異性標(biāo)志物CD44、CD29呈陽(yáng)性表達(dá)(圖2),而造血系統(tǒng)相關(guān)抗原CD34、CD106則呈陰性表達(dá),這說(shuō)明分離培養(yǎng)的細(xì)胞為ADSCs。
2.2ADSCs經(jīng)不同濃度EGF誘導(dǎo)為表皮細(xì)胞后的形態(tài)學(xué)觀察:加入不同濃度EGF定向誘導(dǎo)ADSCs后細(xì)胞形態(tài)仍呈長(zhǎng)梭形或多角形,且HE染色顯示細(xì)胞形態(tài)與未誘導(dǎo)組形態(tài)無(wú)明顯差別(圖3)。
圖1 倒置顯微鏡下觀察ADSCs的細(xì)胞形態(tài)(×40)(a:原代ADSCs培養(yǎng)20min;b:原代ADSCs培養(yǎng)4d;c:原代ADSCs培養(yǎng)7d)
圖2 第3代ADSCs免疫熒光細(xì)胞化學(xué)染色CD29(a)、CD44(b)呈陽(yáng)性,CD34 (c)、CD106(d)呈陰性,×200
圖3 經(jīng)共培養(yǎng)誘導(dǎo)15d后,各誘導(dǎo)組經(jīng)倒置顯微鏡和HE染色觀察細(xì)胞形態(tài)無(wú)明顯變化,細(xì)胞仍呈長(zhǎng)梭形或多角形并且呈魚群樣聚集(3a、3b、3c:×100;3d、3e、3f:×200)
2.3ADSCs誘導(dǎo)培養(yǎng)后免疫熒光細(xì)胞化學(xué)染色:免疫熒光檢測(cè)結(jié)果顯示,7d后誘導(dǎo)組相對(duì)于未誘導(dǎo)組CK-19的表達(dá)量都有不同程度的增多,且10ng/ml組CK-19的表達(dá)量明顯高于其他誘導(dǎo)組,20ng/ml組稍高于5ng/ml組。未誘導(dǎo)組未檢測(cè)到綠色熒光(圖4)。
圖4 ADSCs向表皮細(xì)胞分化鑒定:ADSCs成表皮誘導(dǎo)7d后,免疫熒光細(xì)胞化學(xué)染色,各誘導(dǎo)組(4a:5ng/ml,×200;4b:10ng/ml,×200;4c:20ng/ml,×200)CK-19表達(dá)呈陽(yáng)性,未誘導(dǎo)組(4d:×200)呈陰性。而且10ng/ml組CK-19的表達(dá)明顯高于其他組
2.4熒光定量PCR檢測(cè)CK-19和integrinβ的mRNA表達(dá):經(jīng)熒光定量PCR擴(kuò)增,定向培養(yǎng)誘導(dǎo)后10ng/ml組的CK-19和integrinβ的mRNA表達(dá)明顯高于其他組(P<0.01),差異具有統(tǒng)計(jì)學(xué)意義。20ng/ml組略高于5ng/ml組(P>0.05),差異無(wú)統(tǒng)計(jì)學(xué)意義(圖5)。
圖5 ADSCs經(jīng)不同濃度的EGF處理后表皮細(xì)胞的標(biāo)志性因子CK-19和integrinβ的mRNA表達(dá)
ADSCs來(lái)源于胚胎時(shí)期中胚層,具有向中胚層組織和神經(jīng)外胚層組織等分化的潛力[4]。與骨髓間充質(zhì)干細(xì)胞相似,ADSCs也具有多向分化的潛能,在特定條件下可分化為脂肪細(xì)胞、成骨細(xì)胞、軟骨細(xì)胞[5]、血管內(nèi)皮細(xì)胞、表皮細(xì)胞[6-7],另外有大量學(xué)者報(bào)道了ADSCs亦可向星形膠質(zhì)細(xì)胞[8]、神經(jīng)膜細(xì)胞[9]、尿路上皮細(xì)胞[10]和膀胱平滑肌細(xì)胞[11]誘導(dǎo)分化。相比骨髓干細(xì)胞,
脂肪干細(xì)胞具有來(lái)源豐富、易于獲得以及低免疫原性[12]等優(yōu)點(diǎn)。因此,ADSCs逐漸成為組織工程種子細(xì)胞的更優(yōu)選擇。研究表明,干細(xì)胞在誘導(dǎo)分化為表皮細(xì)胞的過程中,EGF可能是重要的誘導(dǎo)因素[13],其通過參與損失后組織細(xì)胞的增殖分化而發(fā)揮作用,促進(jìn)了細(xì)胞外基質(zhì)的合成,也促進(jìn)了真皮新生血管的生成[14-15],而且還參與誘導(dǎo)皮膚干細(xì)胞增殖分化,加速表皮的再生。因此,我們希望ADSCs能夠成為理想的種子細(xì)胞來(lái)參與缺損創(chuàng)面的修復(fù)。本實(shí)驗(yàn)旨在研究ADSCs被誘導(dǎo)分化為表皮細(xì)胞的可能性以及所需EGF最佳誘導(dǎo)濃度,為今后在皮膚組織工程上的應(yīng)用及發(fā)展提供了一種可能。
在創(chuàng)面修復(fù)過程中,EGF起到了關(guān)鍵性的作用,它不僅誘導(dǎo)干細(xì)胞向表皮細(xì)胞分化,與其受體相結(jié)合,還通過G蛋白偶聯(lián)活化蛋白激酶系統(tǒng)引起細(xì)胞內(nèi)鈣含量的增加及蛋白磷酸化,并通過調(diào)節(jié)基因的表達(dá),誘發(fā)DNA合成促進(jìn)有絲分裂[16],能促進(jìn)細(xì)胞增殖、表皮再生、血管的形成;同時(shí)能夠刺激表皮細(xì)胞合成分泌膠原、透明質(zhì)酸等細(xì)胞外基質(zhì)從而促進(jìn)結(jié)締組織細(xì)胞的生長(zhǎng)[17]。據(jù)報(bào)道,CK-19和integrinβ是表皮干細(xì)胞的重要標(biāo)記物[18-19]。因此,我們采用不同濃度的EGF誘導(dǎo)兔ADSCs,來(lái)觀察其向表皮細(xì)胞的轉(zhuǎn)歸情況。免疫熒光細(xì)胞化學(xué)染色顯示10ng/ml的誘導(dǎo)組細(xì)胞陽(yáng)性表達(dá)CK-19的量明顯高于其他組,而在熒光定量PCR檢測(cè)培養(yǎng)誘導(dǎo)后的CK-19和integrinβ的mRNA表達(dá)中,10ng/ml的誘導(dǎo)組也明顯高于其他組。因此,筆者認(rèn)為ADSCs誘導(dǎo)成為表皮細(xì)胞的過程中,EGF的最佳濃度為10ng/ml。本實(shí)驗(yàn)旨在研究了ADSCs體外誘導(dǎo)分化為表皮細(xì)胞所需EGF的最佳誘導(dǎo)濃度,并未將其移植到在動(dòng)物體內(nèi)以觀察其最終轉(zhuǎn)歸情況,這尚待我們更進(jìn)一步的研究探索。
綜上所述,在治療皮膚缺損中,ADSCs是一種很有前景的治療方法,對(duì)臨床上解決嚴(yán)重創(chuàng)傷、大面積燒傷等患者的皮源缺乏問題以及促進(jìn)創(chuàng)面愈合修復(fù)等問題開辟了一條新途徑。
[1]Zuk PA,Zhu M,Ashjian P,et al.Human adipose tissue is a source of multipotent stem cells[J].Mol Biol Cell,2002,13(12):4279.
[2]Hlata Y.Do not forget the fundamental merits of repair using a tissue expander[J].Plast Reonstr Surg,2002,109(2):819-822.
[3]MF,Mackay AM,Beck SC,et al.Multilineage potential of adult human mesenchymal stem cells[J].Science,1999,284(5411):143-147.
[4]傅士博,王雪,溫從吉,等.脂肪干細(xì)胞在皮膚創(chuàng)傷修復(fù)中的研究進(jìn)展與應(yīng)用前景[J].中華損傷與修復(fù)雜志,2012,7(1):80-82.
[5]Zuk PA,Zhu M,Mizuno H,et al.Multilineage cells from human adipose tissue: implications for cell-based therapies[J].Tissue Eng,2001,7(2):211-228.
[6]Nakano H,Tateishi A,Imamura T,et al.RT-PCR suggests human skeletal muscle origin of alveolar soft-part sarcoma[J]. Oncology,2000,58(4):319-323.
[7]Doherty MJ,Ashton BA,Walsh S,et al.Vascular pericytes express osteogential in vitro and in vitro[J].Bone Mine Res,1998,13(5):828-834.
[8]Zavan B,Michelotto L,Lancerotto L,et al.Neural potential of a stem cell population in the adipose and cutaneous tissues[J].Neuro Res,2010,32(1):47-54.
[9]Ou Y,Yuan XD,Cai YN,et al.Ultrastructure and electrophysiology of astrocytes differentiated from adult adipose-derived stromal cells[J]. Chin Med J,2011,124(17):2656-2660.
[10]Zhu WD,Xu YM,F(xiàn)eng C,et al.Bladder reconstruction with adiposederived stem cell-seeded bladder acellular matrix grafts improve morphology composition[J].World Jurol,2010,28(4):493-498.
[11]楊進(jìn),王坤杰,李虹.人源脂肪干細(xì)胞向膀胱平滑肌細(xì)胞誘導(dǎo)分化的試驗(yàn)研究[J].四川解剖學(xué)雜志,2011,19(2):45-61.
[12]梁爽,袁桂峰,鐘毓娟,等.小鼠脂肪干細(xì)胞的免疫原性及移植安全性[J].中國(guó)組織工程研究,2012,16(1):47-50.
[13]Fu X,Sun X,Li X,Shen Z.Dedifferentiation of epidermal cells to stem cells in vivo[J].Lancet,2001,358(9287):1067-1068.
[14]Planat-Benard V,Silvestre JS,Cousin B,et al.Plasticity of human adipose lineage cells toward endothelial cells: physiological and therapeutic perspectives[J].Circulation,2004,109(5):656-663.
[15]閻賀,張永平,徐淑娟,等.脂肪來(lái)源干細(xì)胞對(duì)兔皮膚組織擴(kuò)張后回縮率的影響[J].中國(guó)美容整形外科雜志,2014,25(6):370-373.
[16]Piazuelo E,Jimenez P,Lanas A,et al.Platelet-derived growth factor and epidermal growth factor play a major role in human colonic fbroblast repair activities[J].Eur Surg Res,2000,32(3):191-196.
[17]Gope R.The effect of epidermal growth factor & plateletderived growth factors on wound healing process[J].Indian Med Res,2002,116:201-206.
[18]Michel M,Torok N,Godbout MJ,et al.Keratin 19 as a biochemical marker of skin stem cells in vivo and invitro: keratin 19 expressing cells are differentially localized in function of anatomic sites and their number varies with donor age and culture stage[J].Cell Sci,1996,109(Pt5):1017-2889.
[19]Jones PH,Watt FM.Separation of human epidermal stem cells from transit amplifying cells on the basis of differences in integrin function and expression[J].Cell,1993,7(4):713-724.
編輯/張惠娟
Effect of different concentrations of EGF on the source of adipose-derived stem cells in rabbits in vitro differentiation in the research of epidermal cells
HU Ya-uan1,YAO Yong-ming1,ZHANG Ze-min1,ZHANG Fan2,WANG Jun1,YANG Biao-bing3
(1.Department of Plastic Surgery,Graduate School,Weifang Medical University,Weifang 261053,Shandong,China;
2.Department of Plastic Surgery,Graduate, The People's Hospital Feixian,Linyi 273400, Shandong,China; 3.Institution of Plastic Surgery,Weifang Medical University,Weifang 261053,Shandong,China)
ObjectiveTo explore the EGF on ADSCs in rabbits in vitro differentiation of epidermal cells and the best concentration for tissue engineering on plastic surgery research provides theoretical basis for further .Explore the EGF on ADSCs in rabbits invitro differentiate of epidermal cells as well as the best optimal concentration needed for tissue engineering to provide further theoretical basis in plastic surgery.MethodsFat isolated from 2 months healthy white rabbit was isolated,cultured,generated ADSCs. Experiment is divided into induction group and not induced group,induced group with 8ng/ml,10ng/ml,20ng/ml of EGF to intervene,not induced group were compared with the same amount of saline.The work also includes observing the different concentration of EGF on ADSCs to epidermis cells in the change of morphology;ADSCs was induced 1 week and detection the expression and of CK-19,and Fluorescence PCR for testing the expression of CK-19 and integrinβ mRNA expression.ADSCs induced by one week of cells by immunofluorescence CK-19 expression was detected,and the fuorescence quantitative PCR to detect CK-19 integrin β of mRNA expression.ResultsInduction of groups with different concentration of EGF was not obvious change in morphology.The shape were still a long fusiform or polygon;Immunofuorescence showed that some cells of EGF for 10ng/ml can be induced group positive expression of the epidermal cells specific markers CK-19 and the number of expression is significantly higher than other groups,not induced group of cells in the test were negative; Fluorescence quantitative PCR results showed that the group of EGF for 10ng/ml expressing specifcity factor CK-19 and mRNA of integrinβ were signifcantly higher than the rest of the group (P<0.01).ConclusionEGF can successfully induced ADSCs to epidermal cells.Different concentrations of EGF on the source of ADSCs in rabbit in vitro differentiation,the best concentration of EGF is 10ng/ml.
Q813.1
A
1008-6455(2016)07-0047-04
山東省醫(yī)藥衛(wèi)生科技發(fā)展計(jì)劃項(xiàng)目(2014WS0470)
楊彪炳,主任醫(yī)師,碩士生導(dǎo)師;研究方向:整形外科,E-mail:ybiaobing@163.com
2016-04-08
2016-07-01